Mater Research
Support Us
Home   Clinical Trials
Back

GDC6599 - A new treatment for chronic cough

Chronic cough

Chronic cough which persists despite medical management may be associated with diseases such as asthma or chronic obstructive pulmonary disease (COPD). Some people experience chronic cough without an identified underlying cause.  There are currently no approved drugs for treatment of any of these forms of chronic cough.

GDC-6599 is a new drug which inhibits the nerve signalling which is believed to be involved in causing chronic coughing.  This trial aims to determine if treatment with GDC-6599 is effective at reducing the frequency and severity of coughing in people with chronic cough. Participants will be assigned at random to receive the study drug or placebo in addition to standard medical care.  The study doctors will monitor participants to determine if the drug is safe and whether there are any side effects.  The study will also measure how well the study drug gets into the bloodstream and how long it lasts in the body. 

Category
Trial Status
Recruiting
Trial Phase
Phase 2 Drug Trial
Registry Listing
Trial contact details
Contact Person
RIO Clinical Trials Unit
Email
Phone
What you need to know

Who can take part?

You may participate in the study if you:

  • Are between 18 and 80 years of age
  • Have been diagnosed with chronic cough associated with asthma or COPD, or chronic cough with unknown cause

You may not participate in the study if you:

  • Are pregnant or breastfeeding
  • Have had COVID-19 in the past 8 weeks

Certain pre-existing conditions and medications may make you unable to participate.  The study doctor will discuss these with you if you are interested in participating.

People who are able to have children must agree to avoid becoming pregnant or fathering a child while participating in the study.

What is involved for you? 

Participants in the study will undertake the following assessments, tests and procedures:

  • Medical history
  • Physical exam
  • Electrocardiogram
  • Neurological exam
  • Blood tests
  • Pregnancy tests (women who can have children only)
  • Urine tests
  • COVID-19 nasal swab
  • Chest X-ray
  • Health questionnaires
  • Lung function tests
  • Sputum sampling
  • Test for reduction of coughing induced by Mannitol
  • Take oral tablets twice a day containing study drug or placebo for 8 weeks

Trial dates

June 2023 to April 2024

Back

All research clinical trials news

2023 was an outstanding year for Mater Research with $13.7 million in grant funding received and 424 publications recorded.

29

Feb

Highlighting Mater Research’s year of achievements: 2023 Annual Report

When Monique Perry was diagnosed with aggressive triple-negative breast cancer she feared her family history was about to repeat itself.

27

Oct

Clinical trials give Queensland breast cancer patients hope

Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.

23

May

Mater launches trial of Australian-first flu vaccine

Displaying results 1-3 (of 18)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >| 

TrIAl Categories

IN THIS SECTION

Skip Navigation Links.